Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Pharvaris's Deucrictibant Immediate-release?
Deucrictibant Immediate-release is a small molecule commercialized by Pharvaris, with a leading Phase III program in Hereditary Angioedema (HAE) (C1...
Data Insights
Risk adjusted net present value: What is the current valuation of Pharvaris's Deucrictibant Immediate-release?
Deucrictibant Immediate-release is a small molecule commercialized by Pharvaris, with a leading Phase III program in Hereditary Angioedema (HAE) (C1...